Suzhou Zelgen Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-03-18
- Employees
- 867
- Market Cap
- -
- Website
- https://www.zelgen.com
The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man
Phase 1
Completed
- Conditions
- Healthy Male Adult
- Interventions
- Drug: [14C]Donafenib
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT04816123
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
Phase 3
Completed
- Conditions
- Myelofibrosis
- Interventions
- Drug: Placebo to match Jaktinib
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 105
- Registration Number
- NCT04617028
- Locations
- 🇨🇳
The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
Phase 2
Completed
- Conditions
- Moderate-to-Severe Plaque Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 123
- Registration Number
- NCT04612699
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
Phase 1
Recruiting
- Conditions
- Advanced Gastrointestinal Tumors
- Interventions
- Biological: KN046 Injection
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT04612712
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- Biological: Toripalimab Injection
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT04605185
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 166
- Registration Number
- NCT04539639
- Locations
- 🇨🇳
The second xiangya hospital of central south university, Changsha, Hunan, China
Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis
Phase 2
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT04507659
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT04503902
- Locations
- 🇨🇳
No.81 Hospital of PLA, Nanjing, Jiangsu, China
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT04472858
- Locations
- 🇨🇳
Shanghai Eastern Hospital, Shanghai, Shanghai, China
Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis
Phase 3
Completed
- Conditions
- Surgical Hemostasis
- Interventions
- Biological: recombinant human Thrombin(CHO cell)Biological: placebo
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 348
- Registration Number
- NCT04459871
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China